Related Experiment Videos
Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases
1Department of Cell and Molecular Biology, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, United Kingdom.
Abstract:
The retinoblastoma tumor suppressor protein, pRB, is inactivated by phosphorylation. While existing evidence is strong that such phosphorylation is mediated by one or more cyclin-dependent kinases (CDKs) active during G1/S, it remains unclear which of the various CDKs is responsible. We show here that three candidate pRB-inactivating kinases, CDK4-cyclin D1, CDK2-cyclin E, and CDK2-cyclin A, phosphorylate pRB differentially, each on a subset of authentic pRB phosphorylation sites. Notably, two neighboring pRB phosphate acceptors, threonine 821 and threonine 826, which have previously been implicated in the regulation of LXCXE protein binding, are phosphorylated by different CDKs. We demonstrate that phosphorylation by either CDK2-cyclin A, which phosphorylates T821, or CDK4-cyclin D1, which phosphorylates threonine 826, can disable pRB for subsequent binding of an LXCXE protein. However, only one of these two kinases, CDK2-cyclin A, can dissociate a pre-existing LXCXE protein-pRB complex. We provide evidence that prior binding of an LXCXE protein blocks access to certain residues specifically targeted by CDK4-cyclin D1, explaining the inability of this kinase to resolve such complexes. While these results are not direct proof of the relevance of differential pRB phosphorylation in cells, our findings support a model whereby full phosphorylation of pRB may require the action of more than one kinase and explains how such differential phosphorylation by different CDKs might translate into a differential regulation of downstream effector pathways.
Insights
Different cyclin-dependent kinases (CDKs) phosphorylate the retinoblastoma protein (pRB) at distinct sites. This differential phosphorylation by specific CDKs, like CDK2-cyclin A and CDK4-cyclin D1, impacts pRB
Area of Science:
- Molecular Biology
- Cell Cycle Regulation
- Cancer Biology
Background:
- The retinoblastoma tumor suppressor protein (pRB) plays a crucial role in cell cycle control.
- pRB inactivation is primarily mediated by phosphorylation, particularly by cyclin-dependent kinases (CDKs) during the G1/S transition.
- The specific CDKs responsible for pRB phosphorylation and their distinct roles remain incompletely understood.
Purpose of the Study:
- To investigate the differential phosphorylation of pRB by candidate G1/S CDKs.
- To determine how specific phosphorylation events by different CDK-cyclin complexes affect pRB function, including LXCXE protein binding.
- To elucidate the mechanisms by which different CDKs regulate pRB activity.
Main Methods:
- In vitro phosphorylation assays using purified CDK-cyclin complexes (CDK4-cyclin D1, CDK2-cyclin E, CDK2-cyclin A) and pRB.
- Analysis of pRB phosphorylation sites using mass spectrometry.
- Assessment of LXCXE protein binding to pRB following specific phosphorylations.
- Investigation of the ability of different CDKs to dissociate pre-existing LXCXE protein-pRB complexes.
Main Results:
- CDK4-cyclin D1, CDK2-cyclin E, and CDK2-cyclin A phosphorylate pRB on distinct subsets of sites.
- Phosphorylation of threonine 821 by CDK2-cyclin A or threonine 826 by CDK4-cyclin D1 can both inhibit LXCXE protein binding.
- Only CDK2-cyclin A, not CDK4-cyclin D1, can dissociate pre-formed LXCXE protein-pRB complexes.
- Prior LXCXE protein binding hinders CDK4-cyclin D1 access to specific phosphorylation sites.
Conclusions:
- pRB phosphorylation is differentially regulated by distinct CDK-cyclin complexes.
- Specific phosphorylation events by different CDKs can differentially impact pRB's interaction with LXCXE proteins.
- A model is proposed where sequential or combinatorial action of multiple CDKs is required for complete pRB inactivation and regulation of downstream pathways.